SHP 610

Drug Profile

SHP 610

Alternative Names: HGT-1410; Recombinant human heparan N-sulfatase - Shire; rhHNS - Shire; SHP610

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Shire
  • Class Enzymes
  • Mechanism of Action Heparan sulfate sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mucopolysaccharidosis III

Most Recent Events

  • 01 Nov 2016 Shire discontinued a phase II extension trial for Mucopolysaccharidosis III (In children and infants) in Spain due to unmet primary endpoints in a previous phase IIb study (NCT02350816)
  • 01 May 2016 Shire completes a phase IIb trial in Mucopolysaccharidosis III (In infants, In children) in USA, Argentina, France, Germany, Italy, the Netherlands, Spain and the UK (NCT02060526)
  • 01 Apr 2015 Shire initiates a phase II extension trial for Mucopolysaccharidosis III (In children and infants) in Spain(NCT02350816)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top